published meta-analysis   sensitivity analysis   studies

sofosbuvir and daclatasvir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsMobarak S (DISCOVER), 2021 1.10 [0.77; 1.57] 1.10[0.77; 1.57]Mobarak S (DISCOVER), 202110%1,083NAnot evaluable deathsdetailed resultsMobarak S (DISCOVER), 2021 1.15 [0.80; 1.67] 1.15[0.80; 1.67]Mobarak S (DISCOVER), 202110%1,083NAnot evaluable mechanical ventilationdetailed resultsMobarak S (DISCOVER), 2021 1.52 [0.72; 3.19] 1.52[0.72; 3.19]Mobarak S (DISCOVER), 202110%1,083NAnot evaluable recoverydetailed resultsMobarak S (DISCOVER), 2021 0.97 [0.89; 1.05] 0.97[0.89; 1.05]Mobarak S (DISCOVER), 202110%1,083NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-16 09:56 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 815 - roots T: 290